[Comment] EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation
Lung cancer is diagnosed in 1 ·8 million people worldwide each year. About 40% of these patients will present with advanced non-small-cell lung cancer (NSCLC). Therapeutic advances in advanced NSCLC include targeted therapies directed against EGFR.1 EGFR expression on the surface of tumour cells has been studied as a therapeuti c target for monoclonal antibodies.2 Cetuximab treatment improved survival of patients when added to platinum-based first-line chemotherapy compared with chemotherapy alone and this benefit had a hazard ratio (HR) of 0·77 (95% CI 0·64–0·93) in patients with squamous cell NSCLC.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Robert Pirker Tags: Comment Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Erbitux | Lung Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma